PARTNERSHIP

As a pioneering biotech company, SunVax has developed diverse innovative technologies which was powered with a serial of IP portfolio (Ionizable lipid Compounds and Lipid Nanoparticle Compositions, Synthetic Self-Amplifying mRNA Molecules With Secretion Antigen and Immunomodulator, Modular Lipid Compounds and Two- To Three-Component lipid nanoparticle compositions, Compositions and Methods for Delivering Molecules, Methods for Cascade Amplifications of Therapeutic Payloads (CATP) & Composition for Cancer Immunotherapies and Gene Therapy, pending), including cell-type-specific-LNP delivery systems and vaccination platforms. To circulate these propriety innovations and expediate the progress in searching for therapeutic drugs to prevent and treat human medical conditions, SunVax offers IP-powered partnerships for vaccination-driven and cell-type-specific-delivery-prompted drug discoveries.

Vaccination-driven drug discovery is reshaping the future of medicine by unlocking powerful, targeted immune responses across some of the most challenging therapeutic areas including cancer treatment and infectious disease prevention/treatment. Next-generation vaccines are being engineered to train the immune system to recognize and destroy cancer cells with unprecedented precision. Vaccines against infectious diseases are evolving beyond prevention-serving as rapid-response platforms that can be adapted to emerging threats in record time. This approach can also accelerate antibody discovery, enabling the identification of highly specific, potent antibodies directly from immune responses, especially to those antigens of membrane proteins. 

Cell-type-specific LNP delivery prompts drug discovery entering a new era with precise, in vivotargeting that was previously out of reach. By delivering mRNA directly to selected cell populations, SunVax can generate in vivo CAR therapies without the need for complex ex vivo manipulation, dramatically simplifying treatment workflows. This platform also powers mRNA-based gene editing, allowing for highly controlled, tissue-specific corrections at the genetic level. Additionally, mRNA-based drug loading opens the venue to program cells to produce therapeutic agents in exactly where they are needed. This technology transforms complex biology into actionable insights-reducing timelines, lowering costs, and increasing the probability of clinical success. Precision delivery isn’t just an advantage-it’s the future of drug discovery. If you are interested in the partnership, please contact via partners@sunvaxmrna.com